Miliary tuberculosis following negative latent tuberculosis infection screening prior to tumor necrosis factor-α antagonists: implications for management?
Benjamin W
BW
Teh
Alan C
AC
Street
Emma S
ES
McBryde
Justin T
JT
Denholm
D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D005188:False Negative Reactions; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D055985:Latent Tuberculosis / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D008403:Mass Screening; D013902:Radiography, Thoracic; D014374:Tuberculin Test; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab